Updated:
Terra Magnum Capital Partners
Terra Magnum Capital Partners is a China-focused private equity firm with over $800 million in assets under management. The firm has made 12 investments,...
Terra Magnum Capital Partners
Terra Magnum Capital Partners is a China-focused private equity firm with over $800 million in assets under management. The firm has made 12 investments, including a Series C investment in Iambic Therapeutics on November 10, 2025. Terra Magnum Capital Partners has also achieved 8 portfolio exits, with Maze Therapeutics being its most recent exit on January 31, 2025.
General information
Firm type
Private Equity
Year founded
2016
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Frequently asked questions
What investment stages does Terra Magnum Capital Partners target?
The firm targets a broad range: seed, start-up, early-stage venture, growth, expansion, and PIPE transactions. This full-lifecycle approach allows Terra Magnum to deploy capital from initial formation rounds through to pre-IPO placements. The multi-stage mandate is structured to retain exposure to portfolio companies as they mature, rather than exiting at a single inflection point.
How is Terra Magnum structured — does it operate as a fund or a deal-by-deal vehicle?
The firm is structured as a private equity asset manager making both direct co-investments and venture generalist commitments. The strategy list indicates capacity for primary fund commitments alongside direct deals, which suggests a hybrid deployment model rather than a pure direct-investment shop. Specific fund vehicles and vintages have not been publicly disclosed.
Where does Terra Magnum source its deal flow?
The firm is headquartered in Beijing and focuses on China-based private companies. Deal flow likely originates through Beijing's startup ecosystem — a dense network of entrepreneurs, university spinouts, and state-affiliated technology programs. The PIPE strategy line indicates additional sourcing capacity through relationships with publicly listed Chinese companies seeking private placement capital.
Does Terra Magnum participate in fund commitments or only direct deals?
The documented strategy includes both direct co-investment and venture generalist categories, which typically encompass fund commitments alongside direct positions. This blended approach is common among China-based managers seeking diversified exposure without building large internal origination teams for every sector. The exact ratio of fund commitments to direct deals has not been publicly reported.
What is Terra Magnum's known posture on co-investments alongside external GPs?
Co-investment is explicitly listed among the firm's core strategy tags, confirming that Terra Magnum actively participates in deals alongside other general partners. This co-investment capability likely serves both as a fee-efficient deployment channel and as a relationship-building mechanism with larger institutional managers active in China.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: